Beauty Should Never Require Gambling With Cancer -By Fransiscus Nanga Roka

Women ought not need to compromise the social recognition of how they look for confidence in a sound body. The lawsuit over chemical hair-relaxers raises an uncomfortable question: who takes the risk when beauty is being aggressively marketed but long-term safety is unclear?

Federal records indicated 12,129 pending cases in MDL 3060 before Northern District of Illinois Judge Mary Rowland as of Sept. The figure counts lawsuits, not injuries that have been proven to result from a product. But it calls for a hard look at what manufacturers sold, were aware of and consumer was informed.

The Sister Study controversy was further inflamed by the 2022 NIH Sister-Study. The finding comes from a study of 33,947 women followed through almost 11 years during which time there were identified to be 378 uterine cancers. Those who reported using a straightener at least 4 times in the previous year had more than double the risk compared to those who did not within two years. Among frequent users, the estimated risk of uterine cancer by age 70 was 4.05% versus:

Those figures deserve attention and accuracy. This is an observational study that points to a correlation but does not prove that any specific brand caused cancer in an individual woman. We did not collect product branding or formulation data. Burns from this route provide a viable exposure pathway through potential chemical absorption, not a completed causal explanation.

Honest investigation of scientific uncertainty It must not become a corporate get out of jail free card or a permission slip to call any well substantiated claim as done.

Arizona Attorney General Kris Mayes announced a consumer-fraud suit against multiple entities owned by L’Oréal, citing undisclosed cancer risks as well as marketing that targeted Black women and children on September 11. L’Oréal says its products are safe and disputes the legal and scientific merit of the claims.

The racial element requires more than corporate diversity jargon. But when straight hair is a requirement of perceived professional-grooming, outside the purview of “consumer choice.” The marketplace of a pressure to alter natural looks cannot be determined by purchase receipt alone.

Yet justice requires specificity. Which formulation? Which exposure period? Which warning? Which internal study? However, a mountain of lawsuits will never replace those answers.

Regulation requires equal precision. And not every chemical relaxer or reproductive-cancer claim should be equated with formaldehyde-related hair-smoothing dangers. A federal regulatory agenda includes a proposed rule on formaldehyde and formaldehyde-releasing ingredients in certain heated hair products for November 2026. However, a scheduled proposal is NOT an enforceable ban.

Five priorities for governments and courts.

First, stricter requirements for firms to disclose full formulations, historical changes and underlying safety data to regulators. Independent health assessment needs to be reconciled with commercial confidentiality.

Second, ask for safety testing that approximates regular use, including multiple exposures, head damage and reasonable usage by children not just ideal application conditions.

Third, mandate clear, evidence calibrated warnings for products and hold manufacturers accountable when they make safety or gentleness claims. Consumers merit information that conveys uncertainty, while not disguising concern.

Fourth, maintain a robust gatekeeping function for expert evidence without creating further procedural delay. An equitable compensation system must be based on documented injury and exposure with understandable fee arrangements and real claimant involvement.

Work to create collective action for international ingredient monitoring and workplace/school protection of natural hairstyles. Product regulation is marching to a different drum than other areas of freedom from appearance-based discrimination.

It is up to the plaintiffs to make their case. Manufacturers must substantiate their assurances. Regulators need to explain the rate of protection.

Women should not bear the costs of learning product hazards via getting sick and supping on legal fees and waiting for years. Commercial promises of beauty deserve to be examined before hospital admission, not only thereafter.

Fransiscus Nanga Roka

Faculty of Law University 17 August 1945 Surabaya and Managing Partner Law Firm Victorious Indonesia